Cardiovascular Diseases Clinical Trial
Official title:
Heart Failure Adherence and Retention Trial (HART)
This study will test whether a self-management (SM) intervention, compared to usual care, will reduce the risk for adverse clinical outcome in patients with mild to moderate heart failure.
BACKGROUND:
Heart failure is a major disabling disease for American adults, affecting an estimated 4.9
million individuals. Heart failure is associated with enormous health care expenditures.
This is because it is a progressive chronic condition that is characterized by disabling
symptoms that limit independence and result in multiple hospitalizations and referrals to
long-term care. The emergence of heart failure as a major public health problem is related
to the unintended result of both an aging population and the success in reducing mortality
from cardiovascular disease. Non-adherence to medications is a key problem in the treatment
of heart failure, with adherence rates ranging from 20% to 90%. There is a clear need,
therefore, to develop interventions that improve adherence in patients with heart failure.
DESIGN NARRATIVE:
This is a single-site, partially blinded, randomized clinical trial of 900 patients with
systolic or diastolic dysfunction, and New York Heart Association (NYHA) functional class II
or III. Patients will be recruited over a period of 2 years from seven hospitals. Patients
will be randomly assigned to either a SM intervention or attention control. The SM group
will meet 18 times for 2 hours over 1 year. These group sessions will teach patients how to
use five basic self-management skills (self-monitoring, environmental restructuring, social
support, cognitive restructuring, and the relaxation response) to help build self-efficacy
and maintain it after the treatment has been discontinued. The attention control arm will
consist of an educational intervention which includes 18 mailings of the American Heart
Association Tip Sheets over the course of the first year, plus a telephone follow-up with
the patient after each mailing to check receipt and comprehension of the Tip Sheet, and to
address any questions about the Tip Sheet. Treatment effects will be evaluated using the
primary outcome of hospitalization for heart failure or death, and the secondary outcomes of
progression of heart failure, quality of life, and health care costs. Potential mediators of
effectiveness will include improved adherence and improved psychosocial function.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
Not yet recruiting |
NCT06211361 -
Cardiac Rehabilitation Program in Patients With Cardiovascular Disease
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|